San Diego, CA—Artemis Research is pleased to announce that the Teva TV46000-CNS-30072 RISE Schizophrenia clinical trial Artemis participated in was a success! Teva Pharmaceuticals Industries and its partner MedinCell announced positive results for this Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia.
The CEO of MedinCell said, “Long-acting injectables for schizophrenia are considered to be an innovative treatment option that we believe will make a meaningful difference, yet they tend to be underutilized and only introduced late in the course of the disease. The results of the RISE study are promising and point to the potential for risperidone to be a subcutaneously administered treatment option for patients with schizophrenia.”
Together with our amazing staff we’re advancing medicine for all.
To read more about the announcement and study findings, click here.